Nano-Encapsulation of Plitidepsin: In Vivo Pharmacokinetics, Biodistribution, and Efficacy in a Renal Xenograft Tumor Model
- 618 Downloads
Plitidepsin is an antineoplasic currently in clinical evaluation in a phase III trial in multiple myeloma (ADMYRE). Presently, the hydrophobic drug plitidepsin is formulated using Cremophor®, an adjuvant associated with unwanted hypersensitivity reactions. In search of alternatives, we developed and tested two nanoparticle-based formulations of plitidepsin, aiming to modify/improve drug biodistribution and efficacy.
Using nanoprecipitation, plitidepsin was loaded in polymer nanoparticles made of amphiphilic block copolymers (i.e. PEG-b-PBLG or PTMC-b-PGA). The pharmacokinetics, biodistribution and therapeutic efficacy was assessed using a xenograft renal cancer mouse model (MRI-H-121 xenograft) upon administration of the different plitidepsin formulations at maximum tolerated multiple doses (0.20 and 0.25 mg/kg for Cremophor® and copolymer formulations, respectively).
High plitidepsin loading efficiencies were obtained for both copolymer formulations. Considering pharmacokinetics, PEG-b-PBLG formulation showed lower plasma clearance, associated with higher AUC and Cmax than Cremophor® or PTMC-b-PGA formulations. Additionally, the PEG-b-PBLG formulation presented lower liver and kidney accumulation compared with the other two formulations, associated with an equivalent tumor distribution. Regarding the anticancer activity, all formulations elicited similar efficacy profiles, as compared to the Cremophor® formulation, successfully reducing tumor growth rate.
Although the nanoparticle formulations present equivalent anticancer activity, compared to the Cremophor® formulation, they show improved biodistribution profiles, presenting novel tools for future plitidepsin-based therapies.
Key wordscancer therapy drug delivery nanomedicine plitidepsin polymersomes
Cremophor®:Ethanol:Water (15:15:70 v/v%)
Feed Weight Ratio
High performance liquid chromatography
Maximum tolerated dose
Poly(trimethylene carbonate)-block-poly(glutamic acid)
Terminal half-life time
Apparent volume of distribution at steady state
Acknowledgments AND DISCLOSURES
This work was supported by funding from the European Commission under the seventh framework within the frame of the NanoTher project (Integration of novel NANOparticle based technology for THERapeutics and diagnosis of different types of cancer CP-IP 213631–2).
- 2.Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;197:55–86.Google Scholar
- 4.Rinehart K, Lithgow-Berelloni AM. Novel antiviral and cytotoxic agent. PCT Int. Pat. Appl. WO 91.04985, Apr. 18, 1991K; GB Appl. 89/22,026, Sept, 515 29, 1989; International patent number:115:248086q.Google Scholar
- 8.Gonzalez-Santiago L, Suarez Y, Zarich N, Munoz-Alonso MJ, Cuadrado A, Martinez T, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ. 2006;13:1968–81.PubMedCrossRefGoogle Scholar
- 12.Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol. 2006;17:1371–8.PubMedCrossRefGoogle Scholar
- 20.Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010;16:3260–9.PubMedCrossRefGoogle Scholar
- 21.Ribrag V, Caballero D, Ferme C, Zucca E, Arranz R, Briones J, et al. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma. Haematologica. 2013;98(3):357–63.Google Scholar
- 24.Bristol-Myers Squibb Co. Princeton. Taxol® (paclitaxel) Injection. March 2003. Available from: http://www.acessdata.fda.
- 26.Nuijen B, Bouma M, Henrar RE, Manada C, Bult A, Beijnen JH. Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration. Anticancer Drugs. 1999;10:879–87.PubMedCrossRefGoogle Scholar